Publications by authors named "Michael Aigner"

Claim this Profile
F
Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets.
Janin Dingfelder, Michael Aigner, Jana Lindacher, Pascal Lukas, Cindy Flamann

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis.
Jule Taubmann, Melanie Hagen, Fabian Müller, Andreas Wirsching, Alp Temiz, Michael Aigner

J Rheumatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.
Melanie Hagen, Fabian Müller, Andreas Wirsching, Soraya Kharboutli, Silvia Spoerl, Michael Aigner

Lancet Rheumatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus].
Jule Taubmann, Sebastian Böltz, Melanie Hagen, Andreas Wirsching, Fabian Müller, Michael Aigner

Z Rheumatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis.
Fabian Müller, Raja Atreya, Simon Völkl, Michael Aigner, Sascha Kretschmann

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.
Fabian Müller, Nora Rebecca Schwingen, Melanie Hagen, Julia Katharina Scholz, Michael Aigner

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling.
Nicole Kabella, Florian P Bayer, Konstantinos Stamatiou, Miriam Abele, Amirhossein Sakhteman, Michael Aigner

Sci Signal· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
Fabian Müller, Andreas Wirsching, Melanie Hagen, Simon Völkl, Carlo Tur, Michael Aigner

Nat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.
Melanie Hagen, Fabian Müller, Andreas Wirsching, Soraya Kharboutli, Silvia Spoerl, Michael Aigner

Lancet Rheumatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series.
Janina Auth, Fabian Müller, Simon Völkl, Nadine Bayerl, Jörg H W Distler, Michael Aigner

Lancet Rheumatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients.
Janin Dingfelder, Jule Taubmann, Franziska von Heydebrand, Michael Aigner, Christina Bergmann

Int J Mol Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Tumor Metabolite 5'-Deoxy-5'Methylthioadenosine (MTA) Inhibits Maturation and T Cell-Stimulating Capacity of Dendritic Cells.
Christina Brummer, Katrin Singer, Frederik Henrich, Katrin Peter, Carolin Strobl, Michael Aigner

Cells· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on: Rescue therapy of anti-synthetase syndrome with CD19-targeted CART cells after failure of several B cell-depleting antibodies: reply.
Jule Taubmann, Johannes Knitza, Fabian Müller, Simon Völkl, Michael Aigner

Rheumatology (Oxford)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells.
Melanie Hagen, Fabian Müller, Andreas Wirsching, Soraya Kharboutli, Silvia Spörl, Michael Aigner

Lancet· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Lena Fischer-Riepe, Sareetha Kailayangiri, Katharina Zimmermann, Rita Pfeifer, Michael Aigner

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
Janin Dingfelder, Michael Aigner, Jule Taubmann, Ioanna Minopoulou, Soo Park

Transplant Cell Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retzius sparing robot-assisted radical prostatectomy: optimizing functional results.
Francesco Chierigo, Alberto Caviglia, Valerio Cellini, Stefano Tappero, Michael Aigner

World J Urol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of signature double-negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function.
Nina Eisenhauer, Maurizio Miano, Nora Naumann-Bartsch, Jörg Leyh, Gianluca Dell'Orso, Michael Aigner

Am J Hematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus.
Jule Taubmann, Fabian Müller, Melek Yalcin Mutlu, Simon Völkl, Michael Aigner

Arthritis Rheumatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis.
Tobias Krickau, Nora Naumann-Bartsch, Michael Aigner, Soraya Kharboutli, Sascha Kretschmann

Lancet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.
Armin Gerbitz, Regina Gary, Michael Aigner, Andreas Moosmann, Anita Kremer

Front Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Fabian Müller, Jule Taubmann, Laura Bucci, Artur Wilhelm, Christina Bergmann, Michael Aigner

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy.
Daniel Nunez, Darshil Patel, Jenell Volkov, Steven Wong, Zachary Vorndran, Michael Aigner

Mol Ther Methods Clin Dev· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains.
Hannah Reimann, Carolin Moosmann, Kilian Schober, Vanessa Lang, Johan Verhagen, Michael Aigner

Immunobiology· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment.
Lara Victoria Donhauser, Julia Veloso de Oliveira, Cordula Schick, Wenzel Manlik, Sabrina Styblova, Michael Aigner

J Immunother Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis